Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses
Excerpt from the Article:
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response.
If approved, it holds the potential of providing several years of immunity for COVID-19, thus greatly easing the administration and manufacturing burden for what seems likely to be an endemic disease.
The vaccine, known as MV-014-212, is based on the company’s respiratory syncytial virus (RSV) vaccine, which has Fast Track designation. That vaccine currently is in Phase II trials, where it appears well-tolerated in adults and in children as young as 15 months.
Click the button below to read the entire Article:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?